As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened regulatory scrutiny, the role of the top pharmaceutical API manufacturer has taken on ...

AbbVie invests $380 million to build two new API manufacturing facilities in North Chicago while Bora Pharmaceuticals Co., Ltd. and GSK have renewed a five-year global manufacturing partnership.

CPHI & PMEC China 2026 is set to take place from 16 to 18 June 2026 at the Shanghai New International Expo Centre (SNIEC), building on its extremely successful run over the last few years.

Nigeria’s pharmaceutical manufacturers have delivered their strongest earnings in at least a decade, signalling a sharp ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

Part of AbbVie’s vow to invest $100 billion in the U.S. over the next decade, the two Illinois facilities will make active ingredients for next-generation neuroscience and obesity drugs when they ...

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

Following positive topline results from the pivotal, global Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease type 1 (STGD1), the Company is on track to submit a New Drug ...

A cost-effective Smart Lock platform and SaaS offering for KoreLock-enabled hardware offers consistent, scalable, and ...

All eyes are on Nvidia's fourth quarter results, due after the closing bell on Wednesday, as AI concerns continue to grip ...

As sponsors advanced more niche and personalized modalities, manufacturers were pushed to adopt holistic approaches to safety ...

AbbVie is investing $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its headquarters campus in North Chicago. Construction is set to begin in spring 2026, ...